Nyxoah S.A. (NYXH.BR)
- Previous Close
9.34 - Open
9.40 - Bid --
- Ask --
- Day's Range
9.22 - 9.74 - 52 Week Range
3.79 - 17.60 - Volume
17,475 - Avg. Volume
64,440 - Market Cap (intraday)
275.353M - Beta (5Y Monthly) 0.48
- PE Ratio (TTM)
-- - EPS (TTM)
-1.54 - Earnings Date May 14, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
15.30
Nyxoah S.A., a medical technology company, focuses on the development and commercialization of solutions to treat sleep disordered breathing conditions. The company's lead solution comprises Genio system, a CE-Marked, patient-centric, and hypoglossal neurostimulation therapy to treat moderate to severe obstructive sleep apnea. Nyxoah S.A. was incorporated in 2009 and is headquartered in Mont-Saint-Guibert, Belgium.
www.nyxoah.comRecent News: NYXH.BR
Performance Overview: NYXH.BR
Trailing total returns as of 4/26/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: NYXH.BR
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: NYXH.BR
Valuation Measures
Market Cap
267.90M
Enterprise Value
222.85M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
60.08
Price/Book (mrq)
2.73
Enterprise Value/Revenue
51.25
Enterprise Value/EBITDA
-5.30
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-20.86%
Return on Equity (ttm)
-39.58%
Revenue (ttm)
4.35M
Net Income Avi to Common (ttm)
-43.21M
Diluted EPS (ttm)
-1.54
Balance Sheet and Cash Flow
Total Cash (mrq)
57.75M
Total Debt/Equity (mrq)
12.96%
Levered Free Cash Flow (ttm)
-40.09M
Research Analysis: NYXH.BR
Company Insights: NYXH.BR
NYXH.BR does not have Company Insights